Introduction {#sec1_1}
============

Stroke is the leading cause of morbidity worldwide with a prevalence rate of approximately 250--300/100,000 in the total population \[[@B1]\] in Asian countries, and 28.5 million disability adjusted life years are estimated to be lost \[[@B2]\] due to stroke leaving 60% of stroke survivors dependent on caregivers for their daily activities. Urged by the expectation of functional neuronal replacement, stem cell transplantation has emerged as a 'hope' to cure disease in the last decade. Several studies have evidenced a potential benefit of stem cell grafts in animal models and clinical trials of stroke \[[@B3]\]. It is also postulated that stem cells operate not only through one unidirectional mechanism (e.g. generating neurons) but rather as cellular mediators of a multitude of biological activities that could provide a favorable outcome for neurogenic diseases \[[@B4]\].

Mesenchymal Stem Cells {#sec2_1}
----------------------

Mesenchymal stem cells (MSC) are self-renewing, multipotent cells that can differentiate into bone, cartilage, adipose tissues and neural precursors \[[@B5], [@B6], [@B7]\]. Intravenously administered MSC have been shown to promote engraftment of hematopoietic lineages in cancers and ameliorate graft-versus-host disease \[[@B8], [@B9], [@B10]\]. The only published trial with a 5-year follow-up of functional potential in stroke patients receiving autologous MSC transplantation reported significant improvement in the activities of daily living \[[@B11]\]. MSC possess immunomodulatory properties, limit the local inflammatory response by decreasing activation of microglia and macrophages and impair T-lymphocyte maturation \[[@B12]\].

Recovery as Neural Plasticity {#sec2_2}
-----------------------------

Initial recovery following an acute insult/stroke is mediated by spontaneous internal events, and after a late phase this recovery is remodeled by both external and internal perturbations \[[@B13], [@B14]\]. It has been suggested that 3 months is the time point recognized generally to get the functional status of a stroke victim \[[@B15]\]. Functional neuroimaging investigates the biological mechanism of treatment effects in which blood oxygen level-dependent (BOLD) and diffusion tensor imaging (DTI) techniques are used to study the functionality and integrity of brain areas \[[@B16], [@B17]\].

Stem Cells as Regenerative Medicine {#sec2_3}
-----------------------------------

The emergence of stem cell biology has led to perennial applications in regenerative medicine for stroke aiming to restore plasticity for improving functional recovery \[[@B18]\]. When introduced into the lesioned central nervous system, stem cells can have a positive influence through their intrinsic neuroprotective properties, e.g. production of growth and trophic factors, stimulation of endogenous neurogenesis and modulation of neuroinflammation. They are known to influence the environment by reorganizing the brain, and promoting learning in the form of synaptogenesis and dendritic sprouting \[[@B19], [@B20]\]. Transplanted stem cells also interact with the host tissue by forming connections and by providing 'scaffolds' to an injured brain in order to rescue dysfunctional and dormant cells \[[@B21]\].

Cell therapies are setting new paradigms in regenerative medicine. This research evaluates the safety, tolerance and possible efficacy of intravenous autologous MSC transplantation in chronic stroke assessed clinically and by functional imaging (BOLD and DTI).

Methods {#sec1_2}
=======

Patients diagnosed with stroke (index event) 3 months to 1 year ago, with MRC (Medical Research Council) grade of muscle power for the wrist and hand extensor or flexor muscles of at least 2, and NIHSS (National Institute of Health Stroke Scale) between 4 and 15 who were conscious and able to comprehend were recruited for this study. We excluded patients with bleeding disorders, chronic liver and/or renal failure, progressive neurological worsening, unilateral neglect, neoplasia and with contraindications to MRI, and immunocompromised and pregnant patients.

The patients were divided into two groups matched for age, disease severity, time of stroke onset and lesion size. All the patients were examined by a neurologist and a neurophysiotherapist regarding muscle power (MRC), tone (modified Ashworth) and Fugl Meyer (FM) scale for upper limbs and modified Barthel index (mBI) at baseline, and the 8- and 24-week follow-ups \[[@B22]\]. We used the Edinburgh handedness inventory to assess hand dominance \[[@B23]\]. The detailed flow chart of the study is explained in figure [1](#F1){ref-type="fig"}. BOLD and DTI techniques were performed at baseline, and after 8 and 24 weeks of cell therapy.

The trial protocol and informed consent form were approved by the Institute Committee for Stem Cell Research and Therapy. A neurologist helped in treatment allocation but was not part of the study. Only the functional imaging parameters were blinded in this research.

Procedures {#sec2_4}
----------

*Bone Marrow Aspiration, Expansion and Transplantation*. Bone marrow was aspirated under aseptic conditions from the posterior superior iliac crest of 6 chronic stroke patients. The aspirate was diluted with phosphate-buffered saline, layered over Ficoll density medium and centrifuged at 1,800 r.p.m. for 25 min. The collected mononuclear cell layer was plated at a density of 1 × 10^6^ cells/cm^2^ with Stem Pro MSC SFM basal medium (A-10334, Invitrogen) in a T-25 tissue culture flask and incubated at 37°C/5% CO~2~. The cells were harvested and seeded at 3,000 or 10,000 cells/cm^2^ in triplicate wells of 6-well plates. Throughout the duration of the culture, individual wells remained separate and were propagated individually. On reaching 70--90% confluence, all MSC cultures were harvested using TrypLE™ Express (Invitrogen), counted flow cytometrically and reseeded at the same seeding density till the final required dose of cells was obtained. Nonadherent cells were removed after 24 h and fresh media were again added for incubation \[[@B24], [@B25]\]. The media were exchanged every 3 days and at confluency, the cells were trypsinized and subcultured. All samples were tested for mycoplasma and endotoxins at every third passage using commercially available kits according to the manufacturer\'s instructions. MSC expansion took around 23 ± 3 days. We used an aseptic infusion technique. Cells were directly dissolved in a 250-ml saline bottle and infused intravenously over 2--3 h using a sterile 50-ml syringe. We used a 20-gauge cannula for cell injection. Patients were evaluated for safety, i.e. laboratory tests (hemoglobin, red and white blood cells, platelets, liver and kidney function tests and partial thromboplastin time) 1, 3 and 7 days and 24 weeks after transplantation. As the patients received an 8-week physiotherapy regime after cell transplantation, they were examined and evaluated daily for any adverse reaction.

*Neuromotor Rehabilitation*. The physiotherapy regime administered to all 12 patients was based on the motor imagery \[[@B26], [@B27]\] incorporating learning and repetition of motor learning and lasted 60--90 min 5 days/week for 8 weeks.

*fMRI Acquisition.* Subjects were asked to perform the motor task with the affected hand, with self-paced (minimum 0.5 Hz) fist clenching/extension of the wrist or metacarpophalangeal joint of the hand. BOLD data were acquired using the gradient echoplanar imaging sequence using a 1.5-tesla MR scanner (Avanto, Siemens, Germany). Block design with alternate baseline and activation cycles was used with a total of 90 whole-brain echoplanar imaging measurements (TR = 4,520 ms, TE = 44 ms, slices = 31 and slice thickness = 4 mm) and MPrage sequence with 176 contiguous slices of 1.0-mm thickness \[[@B28], [@B29]\].

*Diffusion Tensor Images.* They were acquired with single-shot echoplanar technique with b values of 0, 400 and 1,000 s/mm^2^ in 20 directions, 128 × 128 matrix, field of view: 230 × 230 mm, TE = 76 ms, TR = 10,726 ms, echoplanar imaging factor = 127 and a slice thickness of 2.3 mm. The termination criteria used were fractional anisotropy (FA) \<0.2 with an angle change \>45°. Seed points as regions of interest (ROI) were drawn in the infarcted area and corticospinal tract in the affected and unaffected hemispheres \[[@B30], [@B31]\]. The selection of ROI for FA were repeated thrice by one rater, and the average value was regarded as the unit of measurement (intrarater reliability 0.88).

Statistics {#sec2_5}
----------

Statistical analysis was done by SPSS 11.5. We used parametric paired sample t test/Kruskal-Wallis test for intragroup and 2-sample t test/Mann-Whitney test for intergroup comparisons with p = 0.05. Repeated-measure ANOVA was used to calculate the difference at baseline, and 8 and 24 weeks.

Results {#sec1_3}
=======

Establishment of Safety {#sec2_6}
-----------------------

The routine laboratory tests 1, 3 and 7 days after the stem cell transplantation were normal for all patients. Flow-cytometric analysis showed phenotype markers which justify these cells as MSC or stromal cells. The cells expressed CD90, CD73 and CD105, and were negative for HLA class II. The mean CD90, CD73 and CD105 were 61, 57.1 and 40%, respectively. The mean cell viability at transplantation was 98% (performed with trypan blue stain); the cells were sterile and endotoxin free during expansion and at the time of injection. There were no early and late adverse reactions observed in patients during and after transplantation. The patients did not report any tumorigenesis, ectopic tissue formation or any behavioral abnormality during the follow-up.

Clinical Results {#sec2_7}
----------------

In the MSC or experimental group (males:females = 2:4), all had right-hand dominance with age = 42 ± 16.4 years (mean ± SD); the mean FM score was 16.6 ± 5.27 at baseline and 29 ± 7.45 after 8 weeks. Patients showed statistically significant improvement when transplanted with stem cells (p = 0.001, t = −8.357). At the 24-week follow-up, the mean FM score was 36.6 ± 7.4, which was higher than the mean at 8 weeks in these patients exhibiting statistically significant improvement (p = 0.001, t = −8.174). Repeated-measure ANOVA was found to be statistically significant at all time measurements, i.e. at baseline and after 8 and 24 weeks. The mean mBI in the MSC group were 48.75 ± 10.56 and 68.75 ± 12.27 at baseline and 8 weeks, respectively (p = 0.0001), and increased to 78.6 ± 11.34 at 24 weeks (p \< 0.05). In the control group (all males with right-hand dominance), mean age was 47.08 ± 9.9 years. The mean FM scores were 16.8 ± 6.1 and 27.1 ± 6.4 at baseline and 8 weeks, respectively. These patients also showed statistically significant improvement between baseline and 8 weeks after therapy, and between 8 and 24 weeks (p \< 0.05) for both FM and mBI scores (table [1](#T1){ref-type="table"}).

BOLD Activation Pattern {#sec2_8}
-----------------------

The laterality index (LI) was calculated in each subject with a threshold of 10 voxels. It was measured with the formula LI = (CL -- I)/(CL + I), where CL = the number of voxels of the contralateral hemisphere to the affected hand and I = the number of voxels for the ipsilateral hemisphere to the affected hand. In the MSC group, the LI of the ipsilesional primary motor cortex (BA 4) did not show statistically significant improvement between 0 and 8 weeks (p = 0.15) and between 8 and 24 weeks (p = 0.98; table [2](#T2){ref-type="table"}). The LI of the ipsilesional premotor motor cortex (BA 6) showed statistically significant improvement (p = 0.01) between 0 and 8 weeks but was not significant between 8 and 24 weeks (p \> 0.05). In the control group, the LI for the primary motor and premotor cortex (BA 4 and BA 6, respectively) was not statistically significant when calculated between 0 and 8 weeks and 8 and 24 weeks.

The FA ratio was calculated as FA of the affected hemisphere (ah) divided by the unaffected hemisphere (uh). The FA~ah~ was decreased compared to FA~uh~ in both groups. We also calculated the fiber density by calculating the number of fibers (FN) and the fiber length (FL) in the given ROI in the affected and the unaffected hemispheres. We calculated the FL~ah~/FL~uh~ ratio, and the FN~ah~/FN~uh~ ratio. In the MSC group, the mean FL~ah~ (mm) were 0.12 ± 0.05 mm at week 0, and 0.14 ± 0.05 and 0.15 ± 0.06 mm after 8 and 24 weeks, whereas in the control arm they were 0.09 ± 0.03, 0.10 ± 0.04 and 0.11 ± 0.04 mm, respectively. There was no significant change in FL in the MSC and control groups after 8 and 24 weeks. The mean fiber density (number) ratio (FN~ah~/FN~uh~) in the MSC group was 0.28, 0.40 and 0.48 at baseline, and 8 and 24 weeks, and 0.25, 0.29 and 0.34, respectively, in the control group (nonsignificant: p \> 0.05).

Comparison between MSC and Control Groups {#sec2_9}
-----------------------------------------

There was no significant difference in baseline clinical and radiological scores between the MSC and control groups, suggesting that the two groups were comparable to study the effectiveness of therapy after 8 and 24 weeks. There was no significant difference in FM and mBI scores after therapy (8 weeks: p = 0.87, t = 0.161 and p = 0.95, t = 0.065, respectively; fig. [2](#F2){ref-type="fig"}) and at follow-up (p = 0.65 and p = 0.75, respectively; fig. [3](#F3){ref-type="fig"}). A meager reduction in the Ashworth tone scale was observed between the two groups (fig. [4](#F4){ref-type="fig"}).

The LI of BA 4 and 6 between MSC and control groups was also statistically insignificant after 8 and 24 weeks (p \> 0.5). There was no statistically significant (p \> 0.05) change in the FA ratio, FL ratio and FN ratio between the two groups after 8 and 24 weeks.

We compared the results of right-hemispheric stroke with the control arm patients after 8 weeks (table [3](#T3){ref-type="table"}). It was found that BA 4 and 6, and the inferior temporal gyrus (fig. [5](#F5){ref-type="fig"}) of the affected hemisphere were active with a cluster count of 40 and 112 voxels, respectively. The results were similar at 24 weeks (cluster activation of 71 and 112 voxels of BA 4 and BA 6, respectively).

Discussion {#sec1_4}
==========

This is the first known trial (to our knowledge) that establishes the safety and tolerance of MSC derived using serum-free media for expansion unlike bovine serum used in the earlier study \[[@B11], [@B12], [@B24], [@B25]\]. We were able to procure 50--60 million cells at a mean of 4 passages in all the 6 patients, which made autologous MSC transplantation feasible. No immunosuppressants were required following transplantation, eliminating the risks associated with MSC therapy. The clinical, laboratory and radiological evaluations did not report any deaths, cell-related complications, stroke recurrence and structural changes in imaging up to the 6-month follow-up.

The MSC group had 5 cortical and 1 subcortical lesions, 2 patients (patients 2 and 4) were hemorrhagic, and the remainder was ischemic with a lesion volume of 12--58 ml. All patients in this group showed significant improvement after 8 and 24 weeks versus baseline. The control patients had 4 cortical and 2 subcortical lesions (volume: 10--55 ml). All patients in this group showed significant improvement after 8 and 24 weeks versus baseline. Using the 2-sample t test, we observed no statistically significant (p \> 0.05) difference in FM, mBI, LI and FA ratios between both study groups after 8 and 24 weeks. However, the mean percentage change in FM scores between 8 weeks and baseline levels and between 8 and 24 weeks were 74.6 and 26.2%, respectively, in the MSC group and 61.3 and 25.8% in the control arm, respectively. The change from baseline to the 24-week follow-up was 120% in the MSC group compared to 102% in the control group, suggesting a minor trend to improvement in patients administered MSC. There was only a minor change in the power of wrist and hand muscles (subjective analysis) compared to the control group, though we observed a decrease in tone in spastic muscles, a lower pain threshold and a better functional performance in the MSC group (fig. [4](#F4){ref-type="fig"}).

In 1 MSC patient (No. 2) who had a large right temporoparietal lesion, we observed a shift in the LI from negative to positive (table [3](#T3){ref-type="table"}). At baseline, there was an increased activation in the supplementary motor cortex (BA 6) compared with the primary execution area (BA 4) in nearly all patients (recruitment principle of plasticity) \[[@B32], [@B33]\]. After an 8-week physiotherapeutic regime, there was an increased number of voxels in BA 6 in both groups. In the MSC group, the premotor and supplementary motor areas (BA 6) had an increased number of voxels active at the 24-week follow-up suggesting the 'focusing' principle of neural plasticity although the LI at the 24-week follow-up was not statistically significant (p \< 0.05) between both groups. We noticed a considerable increase in LI and signal intensity \[[@B34]\] from baseline to 8 weeks indicating that a focused exercise regime which involves vigorous training of the hand leads to increased force of activation performing better in the fMRI task compared to the performance at 24 weeks.

We correlated FM scores with FA ratios at 24 weeks and found no significant difference in improvement between the MSC and the control group, but 4 of 6 patients (patients 1, 3, 5 and 6) in the MSC group showed good recovery at follow-up with FA \>0.6, whereas in the control group only 3 of 6 patients improved. This minute change in the integrity of the motor tract system might have been due to axonal remodeling imposed by the transplanted MSC \[[@B35], [@B36]\] although there was no statistical significant change in FL and FN ratios between the groups.

The dosage of stem cells prescribed in our study was in congruence with previously published trials \[[@B11], [@B12]\] and still ongoing studies \[[@B37], [@B38]\]. The earlier research groups administered 2 × 50 \[[@B11]\], and 200--400 \[[@B39], [@B40]\], 5--10 \[[@B41]\] and 34.6 × 10^6^ cells \[[@B42]\]. Our findings were in agreement with those of other clinical trials as adverse reactions, mortality or any other risk factor were not noted in association with MSC administration of up to 50--60 × 10^6^ cells in chronic stroke patients.

It has been proved that stem cells given intravenously home in the infarcted regions thus promoting functional recovery in chronic stroke rats \[[@B43]\]. However, cell-enhanced recovery has been reported with chronic delivery of cells even 1 month after ischemia \[[@B44], [@B45]\]. The best route of transplantation still needs to be established considering the specific cell type or the mechanism of action underlying the beneficial effect.

We did not find any significant change in the pattern of recovery of ischemic and hemorrhagic stroke. Previous clinical trials recruited both ischemic and hemorrhagic stroke patients but could not elucidate the effect of cells on the type of stroke \[[@B39], [@B40], [@B41], [@B42]\]. We tried to match the patients with respect to lesion volume but could not find any significant change in the volume and the correlation of the same with MSC therapy.

In our study, the safety and feasibility of expansion of these cells was established in 6 patients. However, our results showed no statistically significant improvement in all clinical scores and functional imaging parameters at 8 and 24 weeks. This could be attributed to a very small sample size and the heterogeneity in MSC group patients (1 patient, No. 2, had a large temporoparietal hemorrhage with a very low potential to recover). We explored infusion with stem cells and physiotherapy as a combination therapy to look into behavioral recovery after stroke. Our aim to administer stem cells intravenously was based on the hypothesis that intravenously administered stem cells will help to upregulate growth factors within the body and brain making the host environment conducive for behavioral recovery \[[@B18], [@B19]\], as it is known that enriched environment, physical activity, stress or molecules such as BDNF, VEGF and dextroamphetamines lead to reorganization of brain areas \[[@B46], [@B47], [@B48]\].

Due to the small sample size, non-randomized trial, dose of cells, site and mode of transplantation, cellular milieu and recovery factors after stroke, we could not reach a definite conclusion regarding the potential of MSC in chronic stroke \[[@B49], [@B50]\]. This study shows, however, that autologous MSC transplantation is safe and feasible. More research is required to evaluate the efficacy of MSC transplantation.

![Flow chart depicting the plan of the study.](cee-0001-0093-g01){#F1}
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###### 

Demographic and clinical data in the MSC and the control group at baseline, and 8 and 24 weeks

  No.        Group   Age, years/sex   Months after stroke   Lesion area all MCA territory   Lesion volume ml   CD90 %   CD73 %     CD105 %   Baseline   8 weeks    24 weeks                         
  ---------- ------- ---------------- --------------------- ------------------------------- ------------------ -------- ---------- --------- ---------- ---------- ---------- ---------- ---------- ----------
  1          E       28/F             11                    R frontoparietal (I)            12                 40       40         44        22         52         36         72         44         80
  2          E       20/F             12                    R frontoparietal (H)            58                 52       58         38        11         30         22         42         30         60
  3          E       59/F             7                     R frontal (I)                   34.6               67       65         23        11         40         26         55         32         70
  4          E       35/F             8                     L internal capsule (H)          13.5               45       43         48        14         32         20         53         28         65
  5          E       55/M             9                     R frontal (I)                   14.2               76       76         52        22         52         38         65         44         78
  6          E       55/M             8                     R frontal (I)                   15.1               86       61         35        20         58         32         70         42         82
  **Mean**           **42**           **9.3**                                               **24.5**           **61**   **57.1**   **40**    **16.6**   **44**     **29**     **59.5**   **36.6**   **72.5**
                                                                                                                                                                                                    
  1          C       40/M             10                    L frontal (I)                   55                 \_       \_         \_        11         40         20         55         30         65
  2          C       28/M             12                    R parietal (I)                  12.2               −        −          −         20         52         31         62         38         78
  3          C       42/M             8                     R internal capsule (I)          15.4               −        −          −         12         35         26         52         36         65
  4          C       30/M             12                    L temporoparietal (I)           45.5               −        −          −         11         42         20         50         30         68
  5          C       60/M             7                     L caudate (I)                   10                 −        −          −         24         55         36         65         33         73
  6          C       50/M                                   R frontoparietal (H)            11.2               −        −          −         23         50         30         68         38         72
  **Mean**           **46.5**         **9.3**                                               **24.8**           **-**    **-**      **-**     **16.8**   **45.6**   **27.1**   **58.6**   **34.1**   **70.1**

C = Control; E = MSC; R = right; L = left; I = ischemia; H = hemorrhage.

###### 

BOLD brain activation pattern and voxel counts in BA 4, BA 6 and cerebellum in the MSC and the control group

  Group   Task   Baseline   8 weeks   24 weeks                                                                                                                                                                          
  ------- ------ ---------- --------- ---------- ------- ------- ------ ------- ----- ------ ------- ------- ------ ------- ------- ------ ------- ----- ------ -------- ----- --- ----- ------- ------ ------- ------- ------
  MSC     LFM    −          59        1          86      150     0.27   176     −     −      −       390     1      −       250     1      176     −     −      −        −     −   866   1,254   0.98   660     −       1
                                                                                                                                                                                                                        
  MSC     LFM    786        −         −1         1,044   −       −1     −       −     −      −       −       −      670     230     −0.6   946     179   0.84   220      220   0   620   3,330   0.66   7,270   7,270   0
                                                                                                                                                                                                                        
  MSC     LFM    −          −         −          172     256     0.19   1,012   −     1      −       −       −      13      734     0.96   430     −     1      −        232   1   65    1,544   0.95   640     730     0.46
                                                                                                                                                                                                                        
  MSC     RFM    78         −         1          −       −       −      6,490   −     1      513     −       1      513     −       1      540     −     1      −              −   543   −       1      634     866     0.57
                                                                                                                                                                                                                        
  MSC     LFM    10         24        0.72       98      462     0.65   229     −     1      14      78      0.78   47      1,126   0.91   1,344   −     1      −        770   1   −     1,801   1      −       −       −
                                                                                                                                                                                                                        
  MSC     LFM    −          239       1          56      140     0.42   44      142   0.23   −       605     1      −       575     1      221     −     1      −        550   1   110   430     0.59   1,012   572     0.63
                                                                                                                                                                                                                        
  C       RFM    −          −         −          499     −       1      −       371   1      −       −       −      643     −       1      329     465   0.41   −              −   712   −       −      650     650     −
                                                                                                                                                                                                                        
  C       LFM    −          −         −          −       586     1      1,238   748   0.62   −       212     1      −       824     1      1,295   382   0.77   −        350   1   −     724     1      138     461     
                                                                                                                                                                                                                        
  C       LFM    −          132       1          221     257     0.11   112     223   0.33   −       650     1      13      730     0.96   230     −     1      −        750   1   −     830     1      212     −       1
                                                                                                                                                                                                                        
  C       RFM    −          138       1          1,893   1,462   0.12   −       −     −      −       −       −      712     223     0.49   232     462   0.66   −              −   532   126     0.61   512     512     0.5
                                                                                                                                                                                                                        
  C       RFM    812        421       0.31       232     −       1      289     631   0.69   1,627   −       1      1,462           1      1,128   −     1      1,192-         1   931   −       1      720     −       −
                                                                                                                                                                                                                        
  C       LFM    −          2,861     1          −       2,861   1      2,861   −     1      −       3,542   1      −       4,180   1      3,881   −     1      −              −   −     2,921   1      2,691   2,691   0.5

C = Control; L = left; R = right; RFM/LFM = right/left fist making; CB = cerebellum; BA 4 = primary motor cortex; BA 6 = supplementary/premotor cortex; BA 1--3 = sensory motor cortices; LI = (CL -- I)/(CL + I); CL = contralateral (to the paretic hand); I = ipsilateral (to the paretic hand); CB ratio = I CB/(I CB + CL CB); cluster: 2\*2\*2 mm~3~.

###### 

Comparison of BOLD activation between the MSC and the control group at 24 weeks in right-hemispheric stroke

  Cluster   z score   MNI coordinates (x, y, z), mm   Hemisphere       Area of activation         Brodmann area
  --------- --------- ------------------------------- ---------------- -------------------------- ---------------
  71        4.02      16, −50, 54                     right cerebrum   precentral sulcus          BA 4
  112       2.95      18, −36,46                      right cerebrum   medial frontal gyrus       BA 6
  56        4.05      −54, −36,26                     right cerebrum   inferior parietal lobule   BA 40
  40        4.56      −48,4, −8                       left cerebrum    superior temporal gyrus    BA 22.21
  92        3.97      8, −40, 28                      right cerebrum   cingulate gyrus            BA 31
  95        3.36      −2,18,34                        left cerebrum    cingulate gyrus            BA 32
  87        2.99      −14, −12,20                     left cerebrum    caudate                    caudate body
  115       2.50      −48, −14, −26                   left cerebrum    inferior temporal gyrus    BA 20, 21

One cluster 2^\*^2 ^\*^2 mm^3^. MNI = Montreal Neurologic Institute.
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